Biotricity Inc. develops and commercializes connected cardiac monitoring technologies for physicians, clinics, hospitals, and other diagnostic providers. The company’s core model is to place FDA-cleared devices and software into clinical workflows and earn recurring technology fees based on utilization. Its portfolio includes Bioflux COM, Biocore, and Bioheart, which are aimed at ECG, arrhythmia detection, and continuous heart monitoring use cases. Biotricity has also positioned its Biocore Pro cellular device as a flagship product for broader U.S. commercialization. The company is still in an expansion phase, building sales coverage and market penetration rather than relying on a mature installed base.
10,6 %
80,9 %
−15,0 %
+16,0 %
0.16
0.12
| % | |
|---|---|
| Cardiac monitoring devices | 55% FDA-cleared wearable and connected devices used to capture ECG and arrhythmia data. |
| Monitoring software and analytics | 20% Software components that support data capture, transmission, and clinical review. |
| Recurring technology services | 20% Utilization-based fees charged for access to the company’s monitoring platform. |
| Consumer heart monitoring | 5% Direct-to-consumer monitoring products sold for personal cardiac tracking. |
Biotricity sells primarily to clinicians and care delivery organizations that need cardiac monitoring tools for...
Buy Bioflux COM and Biocore devices to monitor patients for ECG and arrhythmia events and to support diagnostic workflows.
Use connected cardiac monitoring systems to expand diagnostic capacity and improve detection accuracy.
Purchase or deploy the company’s monitoring technology for repeated patient testing and recurring service usage.
Buy Bioheart for personal continuous heart monitoring outside a traditional physician setting.
Biotricity’s commercialization focus is primarily the United States, where it has expanded sales coverage to 31 states...
Biotricity’s strategy is to grow recurring technology fee revenue by placing its devices with clinically focused repeat...
More field coverage is needed to place devices with repeat users and convert clinical demand into recurring revenue.
The business model depends on repeated device use rather than one-time hardware sales.
Newer cleared products can expand the company beyond narrow monitoring use cases into larger patient populations.
Biotricity faces execution risk because its growth depends on a relatively small sales force, limited operating...
Rivals may have longer operating histories, stronger brand recognition, and greater financial and technical resources, making customer acquisition harder.
The company must maintain regulatory approval for devices and manufacturing facilities; failure could halt commercialization or shipments.
A limited number of suppliers could delay production or prevent timely delivery if volumes or pricing become unfavorable.
Investors have limited evidence on scalability, profitability, and long-term customer retention.
Facility access, customer access, and supply chains can be interrupted, reducing demand and increasing costs.
BCDA · Biological Products, (No Diagnostic Substances)
IRTC · Surgical & Medical Instruments & Apparatus
CDIO · In Vitro & In Vivo Diagnostic Substances
CELU · Pharmaceutical Preparations
BMRA · In Vitro & In Vivo Diagnostic Substances
CELC · Services-Medical Laboratories
: 11/08/2026